Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 511,779 |
|
|||||
| News | - | ||||||
| Day High | 5.72 | Low High |
|||||
| Day Low | 5.16 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Rezolute Inc | RZLT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.21 | -3.76% | 5.38 | 16:27:32 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.55 | 5.16 | 5.72 | 5.72 | 5.59 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,440 | 511,779 | $ 5.44 | $ 2,785,671 | - | 0.72 - 6.0999 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:27:31 | formt | 931 | $ 5.38 | USD |
Rezolute Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 226.66M | 39.63M | - | 0 | -51.79M | -1.31 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Rezolute News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RZLT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.14 | 6.0999 | 3.8514 | 5.19 | 648,974 | 1.24 | 29.95% |
| 1 Month | 2.95 | 6.0999 | 2.48 | 3.37 | 1,158,355 | 2.43 | 82.37% |
| 3 Months | 1.83 | 6.0999 | 1.66 | 3.14 | 578,326 | 3.55 | 193.99% |
| 6 Months | 0.85 | 6.0999 | 0.76 | 2.52 | 411,683 | 4.53 | 532.94% |
| 1 Year | 2.07 | 6.0999 | 0.72 | 2.40 | 224,710 | 3.31 | 159.90% |
| 3 Years | 13.47 | 17.39 | 0.72 | 3.03 | 121,345 | -8.09 | -60.06% |
| 5 Years | 20.14 | 21.20 | 0.72 | 3.37 | 106,923 | -14.76 | -73.29% |
Rezolute Description
| Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402. |
